Skip to content

Considerable overlap between HIV and shigellosis epidemics in the UK

Online privacy concerns limit the reach of sexual health messages on social media

Multiple social and health factors associated with irregular attendance at London HIV clinics

DAAs achieve excellent outcomes in real-world settings

Model suggests there are fewer people with HIV in the US than thought, and more of them on therapy

High incidence of HCV reinfection among HIV-positive MSM in Western Europe

Sofosbuvir/velpatasvir cures HCV in 95% of people with HCV and HIV co-infection

David Wyles presenting at ILC 2016. Photo by Liz Highleyman, hivandhepatitis.com

Six weeks of sofosbuvir/ledipasvir is enough to cure acute hepatitis C in HIV-negative people

Prof. Heiner Wedemeyer of Hannover Medical School presenting at ILC 2016. Photo by Liz Highleyman, hivandhepatitis.com

Tenofovir alafenamide works well against hepatitis B with less effect on bones and kidneys

Prof. Henry Chan of the Chinese University in Hong Kong presenting at ILC 2016. Photo by Liz Highleyman, hivandhepatitis.com